CSIMarket


Pmv Pharmaceuticals Inc   (PMVP)
Other Ticker:  
 


 

Pmv Pharmaceuticals Inc

PMVP's Financial Statements and Analysis



Pmv Pharmaceuticals Inc narrowed third quarter of 2023 net loss per share of $-0.34 compare to net loss per share of $-0.40 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.38 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -0.34 $  0 Mill
$+0.06     Unch.    



Pmv Pharmaceuticals Inc 's Revenue fell by 0 % in third quarter of 2023 (Sep 30 2023) year on year, to $0 million and declined by sequentially.


Pmv Pharmaceuticals Inc is

More on PMVP's Income Statement



Pmv Pharmaceuticals Inc 's in thethird quarter of 2023 recorded net loss of $-16.640 million, an improvement compare to net loss of $-18.229 million in III. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-17.436 million realized in previous quarter.

More on PMVP's Growth

Pmv Pharmaceuticals Inc Inventories
In Sep 30 2023 company's net cash and cash equivalents decreased by $-16 million, capital expenditures grew by -2.781-98.42%, to $0 millions compare to same quarter a year ago

More on PMVP's Cash flow Statement


Pmv Pharmaceuticals Inc does not pay out common stock dividend.

In trailing twelve-month period Pmv Pharmaceuticals Inc earned $ 0.10 cash per share, on a free-cash flow basis .

Book value grew by 1.90 % sequentially to $4.84 per share.
Tangible Book value grew to $ 4.84 per share from $ 4.75.

Company issued 3.23 million shares or 7.06 % in Sep 30 2023.


More on PMVP's Dividends

 Market Capitalization (Millions) 86
 Shares Outstanding (Millions) 49
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -73
 Cash Flow (TTM) (Millions $) 16
 Capital Exp. (TTM) (Millions $) -3
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Pmv Pharmaceuticals Inc does not pay out common stock dividend.

In trailing twelve-month period Pmv Pharmaceuticals Inc had $ 0.10 cash flow per share, on a free-cash flow basis .

Book value grew by 1.90 % sequentially to $4.84 per share.
Tangible Book value grew to $ 4.84 per share from $ 4.75.

Company issued 3.23 million shares or 7.06 % in Sep 30 2023.


More on PMVP's Balance Sheets

 Market Capitalization (Millions) 86
 Shares Outstanding (Millions) 49
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -73
 Cash Flow (TTM) (Millions $) 16
 Capital Exp. (TTM) (Millions $) -3
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Pmv Pharmaceuticals Inc Earnings

Pmv Pharmaceuticals Inc: Powering Through Challenges to Rebound Stronger in Q3 2023



The Major Pharmaceutical Preparations industry advisors have recently assessed Pmv Pharmaceuticals Inc's third-quarter financial results for 2023. The company reported an operating loss of $-19.628 million, while no revenue figures have been released yet. These disappointing figures continue to raise concerns about the company's financial stability. This article delves into the recent financial performance, examines the historical context, and highlights the concerning trends that should worry investors.
Lack of Revenue and Ever-Increasing Losses
Pmv Pharmaceuticals Inc's Q3 financial results for 2023 indicate that the company has not generated any revenue. This absence of revenue is especi...

PMVP Reports Operating Deficit of $-20.122 Million in Q2 2023, Highlights Need for Further Financial Insights


Introduction
The Major Pharmaceutical Preparations industry has experienced mixed results in the second quarter of 2023. Pmv Pharmaceuticals Inc, one of the industry contributors, recently reported an operating deficit of $-20.122 million for the period. This article aims to analyze this performance and compare it to the previous year's results.
Q2 2023 Performance
Pmv Pharmaceuticals Inc has reported a significant operating deficit of $-20.122 million for the second quarter of 2023. However, it is worth noting that the company has not yet cited any top-line figures for this period. Therefore, it will be crucial to wait for further financial reporting to gain a complete understanding of the ...


Date modified: 2023-11-12T12:42:27+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com